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Cardiac
Resynchronization Therapy
Antiarrhythmic or Proarrhythmic?*
Anne B. Curtis, MD
Buffalo, New York
Cardiac resynchronization therapy (CRT) has become a
well-established and important therapeutic option in the
management of patients with symptomatic systolic heart
failure. Improvement in quality of life and exercise tolerance
as well as reduction in hospitalizations for heart failure have
been demonstrated repeatedly (1,2). In addition, reverse
ventricular remodeling and improvement in left ventricular
ejection fraction are seen in the majority of patients. Reduction
in mortality has also been shown, whether or not CRT is
combined with an implantable cardioverter-defibrillator (ICD)
(3). However, despite the fact that advanced heart failure is
ssociated with an increased risk of sudden cardiac death, the
ffect of CRT on the risk of ventricular tachyarrhythmias has
ot been as clear cut.
See page 2416
A number of studies have been performed in an attempt to
elucidate the effect of CRT on ventricular arrhythmias. In
studies that showed a beneficial effect of CRT, the main
comparison has usually been between patients who did and
those who did not receive CRT (4,5). The InSync ICD
Registry, on the other hand, analyzed the risk of recurrent
ventricular tachyarrhythmias in responders (defined as 10%
decrease in left ventricular end-systolic volume [LVESV])
versus nonresponders and found a significant decrease in
ventricular tachyarrhythmias in the responders (32% vs. 43%,
p  0.024) (6). In a retrospective analysis of the InSync III
Marquis Study, a 15% reduction in LVESV was associated
with a significant reduction in premature ventricular contrac-
tions and treated ventricular tachyarrhythmias (7).
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of Sanofi-Aventis.Despite these favorable results, it is clear that epicardial left
ventricular pacing reverses the normal direction of activation of
the ventricle, leading to dispersion of repolarization and pro-
longation of the QT interval, which may be proarrhythmic
(8,9). Case reports of patients who have had a marked increase
in ventricular tachyarrhythmias after initiation of CRT support
these observations from basic and animal studies (10).
Most studies of CRT have concentrated on patients with
highly symptomatic heart failure. The success of this ther-
apy has led to exploration of the role in CRT in less severe
heart failure. In the MADIT-CRT (Multicenter Automatic
Defibrillator Implantation Trial–Cardiac Resynchroniza-
tion Therapy) (11), patients with ischemic or nonischemic
cardiomyopathy, an ejection fraction of 0.30, New York
Heart Association functional class I or II symptoms, and a
QRS duration 130 ms were randomized to cardiac resyn-
chronization therapy defibrillator (CRT-D) therapy or an
ICD. There were 1,820 patients randomized in a 3:2 ratio
and followed for an average of 2.4 years. The primary
endpoint, death or a nonfatal heart failure event, was
significantly reduced in the patients who received CRT-D
therapy. In addition, CRT was associated with a significant
reduction in LVESV and improvement in ejection fraction.
In the present substudy of the MADIT-CRT study, the
risk of ventricular tachyarrhythmias was assessed during
follow-up (12). Of the 1820 patients in the main study,
1,372 patients had paired echocardiograms at baseline and
at 1 year. The lack of echocardiographic data in most of the
remaining patients was due to the fact that the U.S. Food
and Drug Administration originally requested that CRT be
turned off during the 1-year echocardiogram. Patients were
divided into high responders (25% reduction in LVESV
at 1 year post-implantation) and low responders (25%
eduction). The relatively high cutoff for response compared
ith some other studies was due to the fact that the overall
esponse rate in the MADIT-CRT study was quite good,
nd a lower cutoff would have included a much smaller pool
f patients in the low-responder group.
The risk of first appropriate ICD therapy for ventricular
achyarrhythmias was significantly reduced in high respond-
rs to CRT-D (12%) compared with low responders (28%);
isk was intermediate in patients who received ICD therapy
lone (21%) (p  0.001 for the overall difference). High
esponders to CRT-D had a significant 55% reduction in
he risk of ventricular tachyarrhythmias compared with
CD-only patients. Consistent with these observations,
ssessment of the response to CRT-D as a continuous
ariable showed a reduction of approximately 20% in all
ypes of ventricular arrhythmias for every 10% reduction in
VESV.
Compared with ICD-only patients, low responders had a
4% increased risk (p  0.08) for ventricular tachyarrhyth-
mias or death and a 40% (p  0.07) increased risk of
ventricular tachyarrhythmias. Although not significantly
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risk of ventricular tachyarrhythmias in low responders. If so,
then epicardial pacing without achievement of ventricular
remodeling may actually be proarrhythmic, making it crit-
ical that resynchronization be accomplished successfully.
By design, the MADIT-CRT study did not include
patients with more symptomatic heart failure, and so it is not
certain whether the results of this study would pertain to such
patients. We also have no information on actual lead position
in these patients. Left ventricular leads should be placed in a
lateral or posterolateral position to maximize the chances of
achieving resynchronization. Suboptimal lead position could
promote ventricular tachyarrhythmias by dispersion of repolar-
ization as well as by failure to achieve reverse ventricular
remodeling with continued or progressive heart failure.
Despite these minor limitations, this study is valuable in
that it confirms and extends the results of previous studies to
a population of patients with milder heart failure. Key
factors to note are the relatively long follow-up period, large
number of patients in the study, different patient population
compared with those of previous studies, and analysis of
response as a continuous measure in addition to a dichoto-
mous approach. Importantly, lack of response to CRT-D
was associated with a greater frequency of ventricular
tachyarrhythmias than patients treated with ICD therapy
alone.
We can conclude that CRT in mild heart failure, when it
is successful in promoting reverse ventricular remodeling, re-
duces the risk of ventricular tachyarrhythmias compared
with ICD therapy alone. On the other hand, biventricular
pacing with epicardial left ventricular pacing without
improvement in ventricular size and function appears to be
proarrhythmic. It is thus incumbent upon us to select
patients for CRT carefully who have the most likelihood of
responding to resynchronization and to make every effort to
place the lead optimally. Demonstrable structural response
to CRT remains the best insurance that patients will have
optimal outcomes in follow-up.
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